-+ 0.00%
-+ 0.00%
-+ 0.00%

Connect Biopharma Expects To Report Topline Data From Phase 1b Intravenous Administration Study In Q1 And Seabreeze STAT Studies In Acute Asthma And COPD Midyear

Benzinga·01/12/2026 13:12:37
Listen to the news

– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –

– Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 –

– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in mid-2026 –

– Strong balance sheet with cash runway into 2027 through key clinical catalysts –

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026.